NCT02607319View on ClinicalTrials.gov

Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure

PHASE4CompletedINTERVENTIONAL

Enrollment

165

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions

Sterility

Interventions

DRUG

Bemiparin sodium

Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.

Trial Locations (1)

Unknown

American University of Beirut Medical Center, Beirut

All Listed Sponsors

lead

American University of Beirut Medical Center

OTHER

NCT02607319 - Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure | Biotech Hunter | Biotech Hunter